Objective: The aim of this study was to determine the effects of 10 and 20 mg/day of escitalopram on objectively recorded hot flashes and on the rectal temperature threshold for sweating.
H ot flashes (HFs) are triggered by small elevations in core body temperature (Tc) acting within a greatly reduced thermoneutral zone, that is, the range of Tc within which neither sweating nor shivering occurs. 1 This reduction is due to increased sympathetic activation and estrogen withdrawal, among other factors. 2 The first mechanism is supported by the following data. First, plasma 3-methoxy-4-hydroxyphenyl-glycol is greater at baseline in symptomatic versus asymptomatic postmenopausal women and increases significantly further during HFs. 3, 4 Second, drugs that increase sympathetic activation, such as yohimbine, provoke HFs, whereas those that inhibit it, such as clonidine, ameliorate them. 5, 6 From these studies, we infer that the levels of central norepinephrine are higher in symptomatic compared with asymptomatic women.
Research in animals has shown that norepinephrine and serotonin (5HT) work in opposite fashion, 7 suggesting that drugs that increase brain 5HT will ameliorate HFs. Selective serotonin reuptake inhibitors increase 5HT in the synaptic junction by inhibiting its reuptake. Several such drugs, such as citalopram, have shown some efficacy in reducing HFs. 8, 9 Citalopram is a racemate consisting of a 1:1 mixture of the R(j)-and S(+)-enantiomers. In vitro studies have shown that the 5HT reuptake inhibitory activity is entirely attributable to the S-enantiomer, escitalopram. In fact, these studies have also shown that R-citalopram in citalopram actually inhibits the effect of the S-enantiomer. For these reasons, escitalopram is more potent than citalopram for a given dose and is, therefore, a better therapeutic choice. 10 We, therefore, sought to determine the effects of escitalopram upon HFs using an ambulatory recorder and to examine some of its underlying mechanisms by measuring the Tc sweating threshold, which is the upper bound of the thermoneutral zone. We performed a preliminary study and a larger study using successively higher doses of this compound.
METHODS

Participants
Forty-two postmenopausal (at least 1-y amenorrhea) women participated in these studies. There were 16 women in the preliminary study and 26 women in the larger study. They were recruited using ads in local newspapers requesting participants for research on menopause.
Sample size was determined in the following manner. The recent controlled trial of citalopram found a 60% reduction in HF frequency for this drug. 8 In our previous studies, we have found no placebo effects on HFs using ambulatory skin conductance level monitoring. 11, 12 To be conservative, for the present study, we assumed a 25% reduction in ambulatory HF frequency for the placebo group. We used the SDs from the published citalopram study. 8 Using these assumptions in a power analysis, n = 16/group will yield a power of 0.99 for both time (pre/post) and treatment Â time at > = 0.05.
Procedures
Potential participants were first interviewed by one of us (M.E.T., a board-certified psychiatrist) to determine their suitability for the study. Participants were required to report at least six HFs/day, be in the age range of 44 to 59 years; be free of any antidepressant drugs, HF treatment drugs, or supplements (soy, herbs); have body mass index (BMI) less than 32 kg/m 2 ; and be nondepressed as determined by Dr. Tancer using the MINI International Neuropsychiatric Interview, a short, structured, psychiatric interview. Dr. Tancer obtained written informed consent from all participants, and all procedures were approved by the Wayne State University Human Investigation Committee. Women were paid for their participation.
Participants then had their Tc (rectal) sweating threshold determined using the following methods. All sessions were conducted between 1300 and 1800 hours. Participants wore cotton hospital scrub suits, and data were recorded in a sound-proofed, temperature-controlled, and humidity-controlled (25-C; 50% relative humidity) room. They were placed in a semirecumbent (45-) position in a large reclining chair. This session was performed during weeks 1 and 8 at the same time of the day.
Rectal temperature was recorded with a disposable Yellow Springs thermistor (YSI, Yellow Springs, OH) inserted 10 cm into the rectum. The probes are 3 mm in diameter, are flexible, and were well tolerated in the present and previous studies. The probe remained in place for the entire session, typically about 2 hours. Sweating activity was recorded by capacitance hygrometry with a 3.5-cm-diameter plastic chamber attached over the sternum. Compressed air, regulated at 200 mL/minute, was dried over CaCO 2 and passed through the chamber. The minimal level of sweat detection was 0.001 mg/cm 2 per minute as described elsewhere. 2, 4 These signals were digitized at 100 Hz by a Data Translation A/D converter and recorded on a personal computer. The Tc sweating threshold was defined as the rectal temperature at the first measurable detection of sweating.
HFs were assessed using a recorder developed by one of us (R.F.; Flashmark Pro; Pending US Patent No. 60,741,376). 13 The device counts HFs by measuring humidity on the chest. There is no electrical connection to the body. The device contains a humidity sensor, microcontroller, flash memory, and 1.5-V hearing aid battery. The adhesive collars are made from a Food and Drug AdministrationYapproved material (3M #5122). When compared with HFs recorded using the sternal skin conductance level, the positive predictive value was 95.6%, the specificity was 95.2%, and the sensitivity was 90.9%.
Participants were instructed to wear the recorder continuously except while bathing. They were then sent home for 1 week.
After 1 week, participants returned to the laboratory where the HF data were downloaded from the recorder. They wore the recorder for the next 2 weeks and for the 8th week of the study. The participants were then given a blinded bottle of 56 capsules, to be taken once per day at bedtime at the beginning of week 2. In the preliminary study, 10 mg/day was used as the maintenance dose. In the larger study, 20 mg/day was used as the maintenance dose. The corresponding tapering doses were 5 and 10 mg/day, respectively. The tapering doses were given for 2 weeks, when the women had completed the 8 weeks at the maintenance dose. Assignment to the drug groups was random.
Escitalopram was obtained from the manufacturer (Forest Labs) and rebottled, blinded, coded, and randomized by Nathan Worthing, PharmD (Clark Professional Pharmacy, Ypsilanti, MI), who kept the blinding code. Randomization was done using SPSS. The placebo and active drug capsules were identical.
Data analysis
Group differences in demographic variables that were continuous (age, BMI, years in menopause) were analyzed with independent-samples t tests; categorical variables (race, type of menopause) were analyzed with W 2 tests. Sweating threshold data were analyzed using two-way (group Â time), repeated-measures analyses of variance.
HF frequencies were obtained from the ambulatory recorder; an HF was defined as a change in humidity of at least 3% per minute. 13 Data from the preliminary study were analyzed using a two-way, repeated-measures analysis of variance. Data from the second study were analyzed with a two-way (group Â time), repeated-measures analysis of covariance using BMI as a covariate. To control for differences in HF frequency at baseline (week 1), data from subsequent weeks were expressed as percentages of the week 1 data. The minimal level of statistical significance for all analyses was P = 0.05.
RESULTS
For the preliminary study, 19 participants were screened; 3 discontinued (1 had illness, 1 lost interest, 1 moved away). Thus, 16 participants completed this study.
There were no significant group differences on any demographic variables ( Table 1 ). There were no group differences approaching statistical significance in HF frequencies or sweating thresholds. Therefore, the second study was initiated ( Table 2) .
For the second study, 31 participants were screened. Four participants discontinued (2 lost interest, 2 had insufficient time). One participant was screened out at interview due to depression. Thus, 26 participants completed this study.
In this study, the active drug group had a significantly (P G 0.05) higher BMI than did the placebo group. Therefore, BMI was used as a covariate in the following analyses. There was a significant effect for group in the analysis of covariance (P G 0.05, Table 3 ). The average decline in HF frequency at week 8 was 14.4% for the active drug group versus a 6.7% increase for the placebo group. There were no other significant effects from this analysis. The raw HF frequencies are shown in Table 4 . There were no significant effects whatsoever from the analysis of these data or for the analyses of the sweating threshold data.
DISCUSSION
In our preliminary study, we found no significant effects of escitalopram on HF frequency at a dose of 10 mg/day. At a dose of 20 mg/day, we found a significant overall effect of group (escitalopram vs placebo). At week 8, the escitalopram group showed an average decline in HF frequency of 14.4%, whereas the placebo group demonstrated an average increase of 6.7%. However, there were no significant effects across time in either group. From these data, we conclude that, in the present study, escitalopram had little clinical utility in the treatment of HFs in nondepressed women.
Our study is important because it is the first controlled investigation published, to date, of the treatment of meno-pausal HFs in women screened to be free of clinical depression. A pilot study found significant declines in self-reported HF frequency and severity, but there was no placebo control group. 14 A flexible-dose study of escitalopram in depressed women found improvement in menopausal symptoms on the Greene Climacteric Scale, but again, there was no placebo control group. 15 Consistent with its lack of effects on HFs, escitalopram had no significant effects on the sweating threshold for rectal temperature. A previous study of estrogen conducted in our laboratory showed that 1 mg/day P.O. 17A-estradiol significantly increased the rectal temperature sweating threshold and decreased HF frequency, whereas no such effects were obtained in women who received placebo. 16 We recently performed a study in which 5-hydroxytryptophan, the immediate precursor of 5HT, also had no effect on objectively recorded HFs. 17 Another recent investigation found no significant effects of acute tryptophan depletion on HFs. 18 Taken together, these results, along with our findings for escitalopram, raise questions regarding the role of the 5HT system in the etiology of HFs.
Our study is distinguished by the fact that HFs were recorded objectively using a miniature, electronic recorder requiring no interventions from the participant. Most HF studies have used diaries as the main endpoint. However, diaries are subject to compliance problems, which result in bias and errors. 19 In addition, HFs are not accurately reported during sleep because awakenings do not always occur. 20 Finally, large placebo effects occur with diary measures but not with objective ones. 19 
CONCLUSIONS
In conclusion, we found that two doses of escitalopram had no significant effects over 8 weeks on objectively recorded HFs in two groups of nondepressed symptomatic women. In addition, we found no significant effects of this drug on the rectal temperature sweating threshold. These results question the clinical utility of escitalopram in the treatment of HFs in this population. However, our findings are limited by our relatively small sample size, and tests in larger groups using longer treatment periods should be conducted. 
